GlobeImmune

Gilead, GlobeImmune collaborate

Tuesday, October 25, 2011

Gilead Sciences and GlobeImmune have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of therapeutic vaccine products for use in conjunction with Viread (tenofovir disoproxil fumarate) and other oral therapies for the treatment of chronic hepatitis B virus (HBV) infection.

[Read More]